You are viewing a preview of...

JAK1 Inhibitors in the Treatment of Interstitial Cystitis

This therapeutic approach would be a novel way to treat Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) with JAK1 inhibitors

Background

BPS/IC is a common chronic pelvic pain condition that affects an estimated 7.9 million women in the US. BPS/IC is characterized by an unpleasant sensation (pain, pressure, burning, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of more than six weeks duration in the absence of infection or other identifiable causes. There is no consensus and recommendations regarding the management of this disease. Mount Sinai researchers demonstrated efficacy of JAK1 inhibitors in an animal model of BPS/IC.

Log in or create a free account to continue reading